Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant Gardasil 9 and Moderna COVID-19 Vaccine in Children 9-11
NCT05119855Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine, elasomeran in human papillomavirus infection, coronavirus disease 2019 (COVID-19), sponsored by Merck & Co.. Started Mar 2022; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccineelasomeran
03
Conditions
human papillomavirus infectioncoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05119855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119855.